20
Participants
Start Date
September 30, 2012
Primary Completion Date
June 30, 2013
Study Completion Date
June 30, 2013
IN NEO
20 mg Neostigmine via intranasal and sublingual administration
IN NEO
40 mg Neostigmine via intranasal administration
IN NEO
60 mg Neostigmine via intranasal administration
IN NEO + IN Glycopyrrolate
Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
IV Visit
2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
VA Medical Center, Bronx, The Bronx
US Department of Veterans Affairs
FED